دورية أكاديمية
Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD.
| العنوان: | Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD. |
|---|---|
| المؤلفون: | Imai J; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan. 282677@tokai.ac.jp., Takashimizu S; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Suzuki N; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Ohshinden K; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Sawamoto K; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan.; Department of Gastroenterology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Mishima Y; Department of Gastroenterology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Tsuruya K; Department of Gastroenterology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Arase Y; Department of Gastroenterology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Yamano M; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Kishimoto N; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Yamada C; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Inoue N; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Moriyama K; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Baba A; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan., Suzuki H; Department of Gastroenterology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Kagawa T; Department of Gastroenterology, Tokai University School of Medicine, Isehara, Kanagawa, Japan., Nishizaki Y; Department of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, Japan. |
| المصدر: | Scientific reports [Sci Rep] 2024 Jun 11; Vol. 14 (1), pp. 13411. Date of Electronic Publication: 2024 Jun 11. |
| نوع المنشور: | Journal Article; Comparative Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
| مواضيع طبية MeSH: | Non-alcoholic Fatty Liver Disease*/diagnosis , Non-alcoholic Fatty Liver Disease*/metabolism , Non-alcoholic Fatty Liver Disease*/drug therapy, Humans ; Male ; Female ; Middle Aged ; Adult ; Metabolic Syndrome/complications ; Prognosis ; Risk Factors ; Disease Progression ; Aged ; Obesity/complications |
| مستخلص: | A novel concept of Metabolic Associated Fatty Liver Disease (MAFLD) was proposed, incorporating metabolic abnormalities such as obesity and diabetes, which are risk factors that affect the prognosis. Non-Alcoholic Fatty Liver Disease (NAFLD), entails fat accumulation in the liver without alcohol consumption and is often linked to obesity, insulin resistance, and metabolic syndrome. However, the broad nature of the disease concept has hindered prognosis accuracy. In this study, we assess the contribution of the impact of diagnostic criteria for MAFLD on metabolic disease progression compared to conventional diagnostic criteria for NAFLD. A total of 7159 patient who were presented to the health screening center in Tokai University Hospital both in 2015 and 2020 were included in the study. Fatty liver was diagnosed using abdominal ultrasonography. The diagnostic criteria for NAFLD were consistent with the global guidelines based on alcohol consumption. The diagnostic criteria for MAFLD were based on the International Consensus Panel. Medications (anti-hypertensive, diabetic, and dyslipidemia medications) were evaluated by self-administration in the submitted medical questionnaire. A total of 2500 (34.9%) participants were diagnosed with fatty liver (FL +), 1811 (72.4%) fit both NAFLD and MAFLD diagnostic criteria (overlap), 230 (9.2%) fit only the NAFLD diagnostic criteria (NAFLD group) and 404 (16.1%) fit the MAFLD diagnostic criteria (MAFLD group) at 2015. Over the next 5 years, medication rates increased in the NAFLD group for anti-hypertensive, + 17 (7.4%); diabetes, + 3 (1.3%); and dyslipidemia, + 32 (13.9%). In contrast, the only-MAFLD group showed a more significant increase with + 49 (12.1%), + 21 (5.2%), and + 49 (12.1%), for the respective medications, indicating a substantial rise in patients starting new medications. Our analysis of repeated health check-ups on participants revealed that the diagnostic criteria for MAFLD are more predictive of future treatment for metabolic disease than conventional diagnostic criteria for NAFLD. (© 2024. The Author(s).) |
| References: | JHEP Rep. 2021 Jan 19;3(2):100231. (PMID: 33748726) PLoS One. 2020 Nov 13;15(11):e0241770. (PMID: 33186403) Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365) Metabolism. 2021 Feb;115:154433. (PMID: 33212070) Gut. 2017 Jun;66(6):1138-1153. (PMID: 28314735) Clin Gastroenterol Hepatol. 2021 Oct;19(10):2138-2147.e10. (PMID: 33348045) Liver Int. 2020 Aug;40(8):1865-1871. (PMID: 32458507) J Hepatol. 2024 Mar;80(3):419-430. (PMID: 37984709) Clin Gastroenterol Hepatol. 2021 Oct;19(10):2172-2181.e6. (PMID: 34033923) Hepatology. 2023 Mar 1;77(3):949-964. (PMID: 35971878) JAMA. 2020 Mar 24;323(12):1175-1183. (PMID: 32207804) Gut. 2020 Sep;69(9):1691-1705. (PMID: 32321858) Hepatology. 2022 Feb;75(2):419-429. (PMID: 34453359) Ann Hepatol. 2023 Jan-Feb;28(1):100762. (PMID: 36182031) Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. (PMID: 28930295) Gastroenterology. 2020 May;158(7):1999-2014.e1. (PMID: 32044314) Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):387-388. (PMID: 32461575) Clin Mol Hepatol. 2023 Feb;29(Suppl):S17-S31. (PMID: 36443926) Diabetes Metab. 2022 Jul;48(4):101344. (PMID: 35346856) BMC Gastroenterol. 2022 May 13;22(1):241. (PMID: 35562658) Liver Int. 2020 Sep;40(9):2082-2089. (PMID: 32478487) Liver Int. 2020 Dec;40(12):3018-3030. (PMID: 32997882) Lancet Reg Health Southeast Asia. 2023 May 24;15:100220. (PMID: 37614359) JHEP Rep. 2021 Aug 08;3(5):100350. (PMID: 34557660) Nutr Metab (Lond). 2023 Jul 6;20(1):30. (PMID: 37415199) |
| معلومات مُعتمدة: | 22K08042 Japan Society for the Promotion of Science |
| فهرسة مساهمة: | Keywords: Fatty liver; Metabolic associated fatty liver disease (MAFLD); Metabolic disease; Non-alcoholic fatty liver disease (NAFLD) |
| تواريخ الأحداث: | Date Created: 20240611 Date Completed: 20240611 Latest Revision: 20240614 |
| رمز التحديث: | 20240614 |
| مُعرف محوري في PubMed: | PMC11166940 |
| DOI: | 10.1038/s41598-024-64301-3 |
| PMID: | 38862756 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-024-64301-3 |